Rebiotix Named Finalist for 2013 Leaders in Health Care Awards
Download this press release (333 KB).
ROSEVILLE, Minn. (September 5, 2013) — Rebiotix Inc. has been named a finalist for the 2013 Leaders in Health Care Awards by Minnesota Business Magazine. The Roseville, Minn.-based clinical-stage biotechnology company is one of three finalists in the Startup category, which recognizes a remarkable new health care company established within the past three years and based in Minnesota. The winners will be announced at an event in Minneapolis on Oct. 29.
Led by some of the top medical and business minds in Minnesota and beyond, Rebiotix Inc. is aggressively pursuing a solution to a critical health concern by utilizing one of today’s most promising areas of medical innovation: the human microbiome. The company has gone from concept to clinical application in less than two years. Rebiotix received Investigational New Drug approval from the FDA in July; its Phase 2 trial is underway.
Rebiotix was founded in 2011 to revolutionize the treatment of patients suffering from debilitating gastrointestinal diseases. The company’s product platform is based on the transplantation of live human-derived microbes into the intestinal track of sick patients and is first in a new class of drugs to address this huge market. Its first product, RBX2660, is targeted at the treatment of patients who are suffering from repeated episodes of Clostridium difficile infection (CDI).
CDI has become one of the most common health-care associated infections in the U.S., affecting more than 700,000 patients annually and linked to more than 14,000 deaths each year. Approximately 20 to 30 percent of patients with CDI who are treated with commonly used first-line antibiotics experience a recurrence. The risk of recurrence increases with each relapse or reinfection. Currently, the only treatments available for patients with recurrent disease are more antibiotics or surgery, both of which have serious limitations. Rebiotix has pioneered a new therapy using live microorganisms derived from healthy humans to treat this debilitating and potentially life-threatening disease.
Rebiotix Inc. is a results-oriented biotechnology company revolutionizing the treatment of challenging gastrointestinal diseases, such as recurring Clostridium difficile infection, by harnessing the power of the human microbiome. The Roseville, Minn.-based company is pioneering practical and non-antibiotic treatments that reverse pathogenic processes and restore healthy gut flora through the transplantation of live microorganisms. For more information, visit www.Rebiotix.com.